Global Health Ltd Q3 FY25 Earnings Analysis
Published 5 Jul 2026 | Healthcare Services | Market Cap: ₹37.9K Cr
Price
₹1,425
Market Cap
₹37.9K Cr
P/E Ratio
66.2
How does Global Health Ltd rank in Healthcare Services?
Compare Global Health Ltd against every Healthcare Services company this quarter on revenue, margins and earnings-call signals.
Global Health Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹1.2K Cr, net profit ₹142 Cr.
Full financials →Earnings Summary
Strong volume growth expected across hospitals, with inpatient volumes increasing by 13% YoY in Q3 FY25. Medanta expects continued volume-driven growth, with inpatient volumes up 13% YoY and outpatient volumes increasing 9% YoY in Q3 FY25.
📊 Revenue & Sales Performance
- →Strong volume growth expected across hospitals, with inpatient volumes increasing by 13% YoY in Q3 FY25.
- →Expansion of bed capacity ongoing: ~1,000 bed additions planned over next 2 years across Lucknow, Patna, Ranchi, and new facilities like Noida.
- →Development of three major greenfield projects (Mumbai Oshiwara, Pitampura, South Delhi) adding ~1,600 beds over 3-4 years.
- →Continuous recruitment of clinical talent and investment in infrastructure to support growth.
- →Focus on increasing bed occupancy and absolute volumes rather than solely occupancy percentage.
- →Increased empanelment with government and corporate healthcare schemes to expand patient base.
- →Growth driven by complex specialties, robotic programs (notably in Lucknow), and broader specialty expansion possibilities.
- →International patient revenue growing, with facilities like Gurgaon and upcoming Noida expected to contribute.
📈 Profitability & Margins
- →Medanta expects continued volume-driven growth, with inpatient volumes up 13% YoY and outpatient volumes increasing 9% YoY in Q3 FY25.
- →Developing hospitals like Lucknow and Patna show strong momentum, driving occupancy and revenue growth.
- →EBITDA margin improved to 27.5% in Q3 FY25 with an 8% YoY increase in EBITDA; PAT grew 16% YoY to Rs. 1,429 million with PAT margin improving to 14.9%.
- →Capacity expansions underway with ~1,000 bed additions planned in next 2 years plus 3 greenfield projects adding ~1,600 beds over 3-4 years, supporting long-term growth.
- →Focus on optimizing operations, increasing specialist clinical talent, and adopting advanced technologies for better case mix and revenue growth.
- →Tariff increases expected to gradually improve ARPOB, currently stable, alongside better case mix management and length of stay optimization.
- →New facilities (e.g., Noida) expected to break even in 2+ years, contributing to overall earnings growth in medium term.
- →Commitment to serve rapidly growing regions (e.g., eastern Uttar Pradesh) offers significant expansion opportunities.
🏗️ Capital Expenditure Plans
- →Total CAPEX guidance for the next 3 to 4 years is around Rs. 3,000 crores (slide 25 of investor presentation).
- →Approximately 1,000 bed additions planned over the next two years in existing hospitals (Lucknow, Patna, Ranchi) and Noida.
- →Three major Greenfield projects underway with about 1,600 beds: Mumbai Oshiwara (500+ beds), Pitampura (700+ beds), South Delhi Greater Kailash (about 400 beds); these are in various approval/construction stages and expected to take 3-4 years.
- →Lucknow hospital expansion includes adding 200 beds within 6 to 9 months, with flexibility for new specialties.
- →Ranchi expansion includes operationalizing a ready-made hospital to scale from 200 to 300-350 beds.
- →Noida hospital construction started in Sept 2022, expected to be operational by summer 2025.
- →Equipment buy-over and additional investment (~Rs. 20-30 crores for equipment buy-over and ~Rs. 20 crores buffer) planned at Ranchi new hospital site.
💰 Fundraising & Capital Structure
- →The transcript does not mention any current or planned fundraising through debt or equity.
- →Yogesh Kumar Gupta shared the company’s cash and debt position: overall cash of Rs. 1,085 crores and gross debt of Rs. 321 crores.
- →CAPEX guidance over next 3-4 years is around Rs. 3,000 crores, with funding likely managed internally or through existing resources.
- →No explicit commentary on new debt or equity raises was provided during the Q3 FY2025 earnings call.
- →The company appears focused on operational expansion and bed additions, with flexibility on investment but no confirmed new fundraising at this stage.
📋 Order Book & Pipeline
- →Total CAPEX guidance for the next 3 to 4 years is around Rs. 3,000 crores (Page 20).
- →This includes projects related to the build-out and expansion of existing hospitals and new specialties (Page 20).
- →Approximately 1,000 bed additions are planned over the next two years in existing hospitals like Lucknow, Patna, and Ranchi, including Noida (Page 6).
- →Three major greenfield projects are underway totaling about 1,600 beds: Mumbai Oshiwara (500+ beds), Pitampura (700+ beds), and South Delhi Greater Kailash (400 beds); these will take 3 to 4 years to commence operations (Page 6).
- →Lucknow hospital expansion to about 950–1,000 beds is ongoing with further clinical and infrastructure investments planned (Page 17).
- →Noida facility construction is expected to be completed and operational by summer 2025 (Page 11).
Key Metrics
Frequently Asked Questions
What were Global Health Ltd Q3 FY25 results?
Strong volume growth expected across hospitals, with inpatient volumes increasing by 13% YoY in Q3 FY25. Medanta expects continued volume-driven growth, with inpatient volumes up 13% YoY and outpatient volumes increasing 9% YoY in Q3 FY25.
What is Global Health Ltd share price analysis?
Global Health Ltd currently shows a neutral. The stock trades at a P/E of 66.2 with a market cap of ₹37,919 Cr. Investors should review the full earnings analysis for detailed insights.
Is Global Health Ltd planning capital expenditure?
Total CAPEX guidance for the next 3 to 4 years is around Rs.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.